HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), oligonucleotides based therapeutics technology (OBT), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment.
HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania.
For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com.
For business development: bd@hitgen.com
Company Details
- Employees
- 78
- Founded
- -
- Address
- Building 6, No. 8 Huigu 1st East Road, Tianfu International Bio-Town Shuangliu District,china
- Phone
- +86 28 85197385
- in****@****gen.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- hitgen.com
- Keywords
- Hit identification, Lead generation, Chemical library synthesis, Early phase R&D, Protein production and purification, DNA encoded libraries, Hit expansion libraries, Screening libraries, Drug Discovery, synthetic therapeutic oligonucleotide, fragment-based drug discovery, structure-based drug design, E3 ligases, targeted protein degradation, new molecular entities, Oligonucleotides based therapeutics.
- HQ
- Chengdu, Sichuan
Hitgen Inc. Questions
Hitgen Inc.'s helpline number is +86 28 85197385
Hitgen Inc.'s website is hitgen.com
Hitgen Inc.'s LinkedIn profile is https://cn.linkedin.com/company/hitgen-ltd
Hitgen Inc. has
78 employees.
View email and phone details for 78
employees at Hitgen Inc..
Hitgen Inc.'s industry is
Biotechnology Research
Hitgen Inc.'s top competitors are
Vernalis,
Bridge Biotherapeutics, Inc.,
Abbvie,
Evotec,
Abiosciences,
Merck Group,
Catalent,
Astrazeneca,
Gsk.
Hitgen Inc.'s support email address is info@hitgen.com
Hitgen Inc.'s categories are Biotechnology Research
Hitgen Inc.'s founding year is 2012
